IGM Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of IGM Biosciences generated cash of -$192,231,000, which is less than the previous year. Cash used in financing activities reached the amount of $115,068,000 last year. Net change in cash is therefore -$8,808,000.
Cash Flow
| 2017 | -10.35M | -385K | 8.06M |
|---|---|---|---|
| 2018 | -20.04M | -788K | 22.33M |
| 2019 | -45.11M | -203.23M | 282.25M |
| 2020 | -67.30M | 57.71M | 214.78M |
| 2021 | -124.33M | 14.81M | 2.47M |
| 2022 | -5.85M | -225.64M | 219.38M |
| 2023 | -192.23M | 68.35M | 115.06M |
IGMS Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 121.92M | 134.03M | 241.08M | 35.89M | 1.98M | 482K | 3.15M |
Operating activities | |||||||
Net income | -246.41M | -221.10M | -165.16M | -81.35M | -43.13M | -22.71M | -11.05M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 8.27M | 6.07M | 4.48M | 1.02M | 597K | 278K | 161K |
Stock-based compensation expense | 46.54M | 44.71M | 25.87M | 8.45M | 1.01M | 0 | 93K |
| Deferred income tax benefit | 46.54M | 44.71M | 25.87M | 8.45M | 1.01M | 0 | 93K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 35K | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | -35K | 0 | 0 | 0 |
Accounts payable | -992K | -3.00M | 652K | 2.19M | 1.96M | -61K | 128K |
Cash generated by operating activities | -192.23M | -5.85M | -124.33M | -67.30M | -45.11M | -20.04M | -10.35M |
Investing activities | |||||||
Purchases Of Investments | -365.03M | -540.02M | -129.34M | -208.56M | -208.90M | 0 | 0 |
Investments In Property Plant And Equipment | -12.38M | -10.20M | -13.24M | -17.50M | -2.33M | -788K | -385K |
Acquisitions Net | 0 | 7.36M | -28.70M | -57.71M | 200.90M | 0 | 0 |
Cash generated by investing activities | 68.35M | -225.64M | 14.81M | 57.71M | -203.23M | -788K | -385K |
Financing activities | |||||||
Common Stock Issued | 113.56M | 217.98M | 4.03M | 216.18M | 187.17M | 0 | 8.06M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -1.55M | -1.73M | -324K | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 15M | 0 | 0 |
Cash used in financing activities | 115.06M | 219.38M | 2.47M | 214.78M | 282.25M | 22.33M | 8.06M |
Net Change In Cash | -8.80M | -12.11M | -107.04M | 205.18M | 33.90M | 1.50M | -2.67M |
Cash at end of period | 113.11M | 121.92M | 134.03M | 241.08M | 35.89M | 1.98M | 482K |
| Data source | Data source | Data source | Data source | Data source |